GO:0071882 phospholipase C-activating adrenergic receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071882 describes a G protein-coupled receptor signaling pathway that begins with ligand binding to an adrenergic receptor and ends with phospholipase C activation and regulation of downstream cellular processes such as transcription.
• The pathway is initiated by catecholamines such as norepinephrine and epinephrine acting on adrenergic receptors, which couple to Gq/11 proteins to stimulate phospholipase C.
• Phospholipase C activation produces inositol trisphosphate and diacylglycerol, second messengers that mobilize calcium and activate protein kinase C.
• Desensitization of receptor-mediated phospholipase C activation can occur after sustained agonist exposure, as shown in isolated hepatocytes treated with ethanol.
• Network pharmacology and molecular docking studies have implicated adrenergic receptor signaling in drug effects such as aripiprazole against hyperprolactinemia.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential for dissecting the causal roles of adrenergic receptors and phospholipase C isoforms in this pathway.
Description
The Gene Ontology term GO:0071882, phospholipase C-activating adrenergic receptor signaling pathway, defines a biological process in which an adrenergic receptor on the cell surface binds its ligand and triggers a G protein-coupled signaling cascade that ultimately activates phospholipase C, leading to regulation of downstream cellular events such as transcription. This pathway is a specialized branch of adrenergic signaling that specifically couples receptor activation to phospholipase C rather than to other effectors such as adenylyl cyclase. Understanding this pathway is important because adrenergic receptors are central to cardiovascular, metabolic, and neurological physiology, and their dysregulation is implicated in diverse diseases. The pathway has been studied in model systems including isolated hepatocytes, where receptor-mediated phospholipase C activation and its desensitization by ethanol were characterized. Researchers investigating this term need precise tools to manipulate the involved receptors and enzymes, and CRISPR-based cell models provide a robust approach for causal interrogation.
phospholipase C-activating adrenergic receptor signaling pathway At A Glance
| GO ID | GO:0071882 |
|---|---|
| GO term | phospholipase C-activating adrenergic receptor signaling pathway |
| Ontology | biological_process |
| Synonym | activation of phospholipase C activity by adrenergic receptor signaling pathway; activation of phospholipase C activity by adrenergic receptor signalling pathway; adrenergic receptor, phospholipase C activating pathway |
| Major function | Couples adrenergic receptor ligand binding to phospholipase C activation and downstream cellular regulation |
| Upstream trigger | Ligand binding to an adrenergic receptor on the target cell surface |
| Key enzyme | Phospholipase C |
| Downstream outcome | Regulation of a downstream cellular process, e.g. transcription |
| Example experimental system | Isolated hepatocytes for receptor-mediated phospholipase C activation and desensitization |
What Is GO:0071882?
GO:0071882 is a biological process term describing a phospholipase C-activating receptor G protein-coupled receptor signaling pathway that is initiated by ligand binding to an adrenergic receptor on the surface of a target cell and ends with the regulation of a downstream cellular process, for example transcription. In other words, it is the sequence of molecular events linking adrenergic receptor occupancy to phospholipase C activation and subsequent cellular responses.
Why Is phospholipase C-activating adrenergic receptor signaling pathway Important in Cell Biology?
GO:0071882 is important because it defines a specific signaling route by which adrenergic receptors, which are major drug targets, can control phospholipase C-dependent second messenger production and gene expression. This pathway is relevant to understanding how catecholamines and adrenergic drugs modulate cellular physiology, and how sustained stimulation can lead to desensitization, as demonstrated in hepatocytes exposed to ethanol. Because the pathway ends with regulation of downstream processes such as transcription, it provides a mechanistic link between extracellular signals and long-term cellular adaptation.
• Defines a distinct G protein-coupled receptor pathway that couples adrenergic receptors to phospholipase C.
• Provides a framework for studying catecholamine effects on second messenger systems.
• Relevant to drug discovery because adrenergic receptors are targets of many pharmacological agents.
• Desensitization of this pathway can occur after sustained agonist exposure, as shown for ethanol in hepatocytes.
• Links receptor activation to transcriptional regulation, connecting acute signaling to gene expression.
• Supports research on cardiovascular, metabolic, and neuropsychiatric conditions where adrenergic signaling is dysregulated.
• Enables mechanistic interpretation of network pharmacology and molecular docking results involving adrenergic receptors.
• Provides a basis for CRISPR-based causal studies of receptor and phospholipase C isoforms.
What Happens During phospholipase C-activating adrenergic receptor signaling pathway?
Ligand binding to adrenergic receptors
In simple terms: A signaling molecule docks onto a receptor on the cell surface, starting the message.
The pathway begins when an agonist ligand binds to an adrenergic receptor on the surface of a target cell. This receptor belongs to the G protein-coupled receptor superfamily and is the initiating component of GO:0071882. The binding event is the first step that commits the cell to phospholipase C-activating signaling rather than other adrenergic pathways.
G protein activation and phospholipase C stimulation
In simple terms: The receptor switches on a helper protein that then turns on an enzyme called phospholipase C.
Following ligand binding, the adrenergic receptor activates a heterotrimeric G protein, which in turn stimulates phospholipase C. This coupling is the defining feature of the phospholipase C-activating adrenergic receptor signaling pathway. The activation of phospholipase C is the central enzymatic event of GO:0071882.
Second messenger production
In simple terms: The activated enzyme cuts a membrane lipid into two messenger molecules.
Activated phospholipase C hydrolyzes membrane phospholipids to generate second messengers, including inositol trisphosphate and diacylglycerol. These messengers propagate the signal inside the cell and are characteristic outputs of phospholipase C activation. Their production represents the downstream biochemical consequence of the pathway.
Downstream cellular regulation and desensitization
In simple terms: The signal changes how the cell behaves, and the cell can later turn the signal down.
The pathway ends with the regulation of a downstream cellular process, such as transcription. Sustained or repeated stimulation can lead to desensitization of receptor-mediated phospholipase C activation, as observed in isolated hepatocytes exposed to ethanol. This desensitization illustrates that the pathway is dynamically regulated rather than a fixed linear cascade.
Key Genes Involved in GO:0071882 phospholipase C-activating adrenergic receptor signaling pathway
The following genes and proteins are central to the phospholipase C-activating adrenergic receptor signaling pathway (GO:0071882) and are commonly studied in this context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRA1A | Alpha-1 adrenergic receptor that couples to Gq and activates phospholipase C | Mediates phospholipase C-activating adrenergic signaling |
| ADRA1B | Alpha-1 adrenergic receptor subtype linked to phospholipase C activation | Target for studying receptor subtype-specific signaling |
| ADRA1D | Alpha-1 adrenergic receptor subtype involved in Gq-coupled signaling | Relevant to pathway specificity and drug responses |
| ADRB1 | Beta-1 adrenergic receptor, primarily Gs-coupled but studied in adrenergic signaling networks | Context for comparing phospholipase C-activating versus other adrenergic pathways |
| ADRB2 | Beta-2 adrenergic receptor, a prototypical adrenergic receptor | Model receptor for adrenergic pharmacology and signaling crosstalk |
| GNAQ | Gq alpha subunit that activates phospholipase C | Key transducer linking adrenergic receptors to phospholipase C |
| GNA11 | Gq family alpha subunit with roles in phospholipase C activation | Alternative transducer for phospholipase C-activating pathways |
| PLCB1 | Phospholipase C beta isoform activated by Gq proteins | Core enzyme of the pathway |
| PLCB2 | Phospholipase C beta isoform | Potential effector in adrenergic receptor signaling |
| PLCB3 | Phospholipase C beta isoform | Candidate effector for Gq-coupled adrenergic receptors |
| PLCG1 | Phospholipase C gamma isoform | Studied in broader phospholipase C signaling contexts |
| PRKCA | Protein kinase C alpha, activated by diacylglycerol | Downstream effector of phospholipase C activation |
| PRKCB | Protein kinase C beta | Downstream mediator of diacylglycerol signaling |
| ITPR1 | Inositol trisphosphate receptor, mediates calcium release | Downstream target of inositol trisphosphate produced by phospholipase C |
| ITPR2 | Inositol trisphosphate receptor isoform | Calcium signaling component downstream of phospholipase C |
| DRD2 | Dopamine receptor studied in network pharmacology with adrenergic signaling | Example of receptor crosstalk in pharmacological studies |
| HTR2A | Serotonin receptor in Gq-coupled signaling networks | Context for comparing phospholipase C-activating pathways |
How Is phospholipase C-activating adrenergic receptor signaling pathway Regulated?
The phospholipase C-activating adrenergic receptor signaling pathway is subject to regulation at multiple levels. Sustained agonist exposure can cause desensitization of receptor-mediated phospholipase C activation, as demonstrated in isolated hepatocytes where ethanol treatment led to reduced phospholipase C responses. This indicates that the pathway is not constitutively active but is tuned by prior stimulation and cellular context. Additionally, network pharmacology studies suggest that drugs such as aripiprazole can modulate adrenergic receptor signaling networks, highlighting pharmacological regulation of this pathway.
phospholipase C-activating adrenergic receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADRA1A | Cardiovascular and metabolic disorders linked to adrenergic signaling | Knockout or point-mutation cell models to test receptor function |
| ADRA1B | Adrenergic signaling in pharmacology and disease | Overexpression and knockout models for pathway dissection |
| PLCB1 | Phospholipase C-mediated signaling in disease | Knockout and knock-in models to assess enzyme contribution |
| GNAQ | Gq-coupled signaling in cellular regulation | Point-mutation models to test G protein activation |
| PRKCA | Downstream signaling in disease processes | Knockout models to evaluate downstream effects |
Adrenergic signaling in hyperprolactinemia and psychiatric pharmacology
Network pharmacology and molecular docking studies have explored the pharmacological mechanism of aripiprazole against hyperprolactinemia, implicating adrenergic receptor signaling among the affected pathways. This suggests that GO:0071882 may contribute to the broader pharmacological effects of drugs targeting adrenergic receptors. Understanding this pathway can help interpret drug mechanisms and side effects.
Ethanol effects and hepatocellular signaling
Ethanol causes desensitization of receptor-mediated phospholipase C activation in isolated hepatocytes, linking this pathway to alcohol-related cellular responses in the liver. This finding indicates that GO:0071882 can be modulated by environmental and pharmacological exposures. It also provides a model for studying how sustained stimulation alters adrenergic signaling.
Cardiovascular and metabolic implications
Adrenergic receptors are central to cardiovascular and metabolic regulation, and their coupling to phospholipase C can influence vascular tone, cardiac function, and metabolic processes. Dysregulation of these pathways is therefore relevant to cardiovascular and metabolic diseases. Studying GO:0071882 helps clarify how adrenergic signals contribute to these conditions.
From phospholipase C-activating adrenergic receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of an adrenergic receptor abolish phospholipase C activation? | Knockout cell model |
| Does a specific receptor mutation alter Gq coupling? | Point-mutation knock-in model |
| Can a tagged receptor be used to track pathway activation? | Tagged knock-in model |
| Does overexpression of phospholipase C enhance signaling? | Overexpression cell model |
| Which genes are required for downstream transcriptional regulation? | CRISPR library screening |
| How does desensitization affect pathway output? | Time-course stimulation in knockout and wild-type cells |
How to Study the phospholipase C-activating adrenergic receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Inositol phosphate accumulation assay | Phospholipase C activity | Direct measurement of pathway activation |
| Calcium imaging | Intracellular calcium release | Downstream second messenger readout |
| Transcriptional reporter assay | Regulation of transcription | Endpoint of pathway |
| Western blot | Protein expression and phosphorylation | Assessing downstream kinase activation |
| Network pharmacology | Drug-target interaction networks | Predicting pathway modulation |
| Molecular docking | Ligand-receptor binding poses | Hypothesis generation for adrenergic drugs |
| CRISPR knockout screening | Gene requirement for pathway output | Identifying essential components |
| RNA-seq | Global transcriptional changes | Downstream effects of pathway activation |
Measuring phospholipase C activity
Phospholipase C activation can be assessed by measuring the production of inositol trisphosphate and diacylglycerol or by using reporter systems that detect second messenger levels. These assays directly read out the enzymatic step central to GO:0071882. In isolated hepatocytes, such measurements revealed desensitization of receptor-mediated phospholipase C activation after ethanol exposure.
Calcium imaging and second messenger detection
Because inositol trisphosphate triggers calcium release, calcium imaging can be used to monitor downstream events of the pathway. This approach provides a dynamic readout of phospholipase C-activating adrenergic signaling. Combining calcium imaging with receptor-specific agonists helps attribute responses to GO:0071882.
Transcriptional reporter assays
Since the pathway ends with regulation of downstream cellular processes such as transcription, reporter assays can quantify transcriptional outputs. These assays link receptor activation to gene expression changes. They are useful for comparing wild-type and CRISPR-modified cells.
Network pharmacology and molecular docking
Network pharmacology and molecular docking can predict interactions between drugs and adrenergic signaling components, as shown for aripiprazole and hyperprolactinemia. These computational methods help generate hypotheses about pathway modulation. They can be combined with experimental validation in cell models.
How CRISPR Can Be Used to Study GO:0071882 phospholipase C-activating adrenergic receptor signaling pathway
Knockout
CRISPR knockout of adrenergic receptors or phospholipase C isoforms can determine whether they are required for GO:0071882. Loss-of-function models help establish causal roles in pathway activation. Such models are particularly useful for distinguishing receptor subtypes.
Point Mutation
Point mutations can be introduced into adrenergic receptors or G protein subunits to test specific residues involved in coupling to phospholipase C. These models allow fine-grained structure-function analysis. They complement knockout studies by preserving protein expression while altering function.
Knock-in
Knock-in of tagged or reporter versions of pathway components enables tracking of receptor localization and activation. Tagged knock-in models can be used for imaging-based readouts of GO:0071882. They also facilitate biochemical isolation of receptor complexes.
Overexpression
Overexpression of adrenergic receptors or phospholipase C can amplify pathway signaling for sensitive detection. These models are useful for studying downstream transcriptional responses. They can also reveal saturation or desensitization effects.
How EDITGENE Supports phospholipase C-activating adrenergic receptor signaling pathway Research
Researchers studying phospholipase C-activating adrenergic receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation, second messenger production, or downstream transcriptional regulation. CRISPR-based cell models provide a precise way to test these hypotheses by deleting, mutating, tagging, or overexpressing the genes of interest.
Contact EDITGENE today to design your custom CRISPR model for phospholipase C-activating adrenergic receptor signaling pathway research.
Frequently Asked Questions About phospholipase C-activating adrenergic receptor signaling pathway
What is GO:0071882?
GO:0071882 is the Gene Ontology term for phospholipase C-activating adrenergic receptor signaling pathway, a biological process initiated by ligand binding to an adrenergic receptor and ending with regulation of a downstream cellular process such as transcription.
What is phospholipase C-activating adrenergic receptor signaling pathway?
It is a G protein-coupled receptor signaling pathway in which adrenergic receptor activation leads to phospholipase C stimulation and production of second messengers.
What genes are involved in phospholipase C-activating adrenergic receptor signaling pathway?
Genes include adrenergic receptors such as ADRA1A, ADRA1B, and ADRA1D, G protein subunits such as GNAQ, phospholipase C isoforms such as PLCB1, and downstream effectors such as PRKCA.
What does phospholipase C do in this pathway?
Phospholipase C hydrolyzes membrane phospholipids to generate inositol trisphosphate and diacylglycerol, which act as second messengers.
How is this pathway desensitized?
Sustained agonist exposure can cause desensitization of receptor-mediated phospholipase C activation, as shown in isolated hepatocytes treated with ethanol.
Which diseases are linked to adrenergic receptor signaling?
Adrenergic signaling has been implicated in hyperprolactinemia pharmacology, cardiovascular and metabolic conditions, and other disorders.
How can I study GO:0071882 in the lab?
You can measure phospholipase C activity, calcium release, and transcriptional outputs, and use CRISPR models to test gene function.
What CRISPR models are useful for this pathway?
Knockout, point mutation, knock-in, and overexpression models can all be used to dissect pathway components.
Is ethanol relevant to this pathway?
Yes, ethanol causes desensitization of receptor-mediated phospholipase C activation in isolated hepatocytes.
What is the role of Gq proteins in this pathway?
Gq proteins couple activated adrenergic receptors to phospholipase C, serving as essential transducers.
Conclusion
GO:0071882 defines a specific adrenergic receptor signaling pathway that activates phospholipase C and regulates downstream cellular processes such as transcription. Its components, including adrenergic receptors, Gq proteins, phospholipase C isoforms, and downstream kinases, are important for understanding catecholamine biology and drug action. The pathway can undergo desensitization, as demonstrated in hepatocytes exposed to ethanol. CRISPR-based cell models offer a powerful approach to causally interrogate the genes involved in this pathway.
References
- 1. Yang L et al.. 2024. Exploring the potential pharmacological mechanism of aripiprazole against hyperprolactinemia based on network pharmacology and molecular docking.. Schizophrenia (Heidelb) 10(1):105 PMID: 39511179
- 2. Higashi K et al.. 1991. Ethanol causes desensitization of receptor-mediated phospholipase C activation in isolated hepatocytes.. J Biol Chem 266(4):2178-90 PMID: 1846616
